Press Conference

147
previously that Dr. Workman was to meet with his advi ory
committee in Ann Arbor right after the report, and that
committee I believe is listed here, and to reach a decision
as to whether we should license or not. They all heard
the report at Ann Arbor. They all then met. And it was
not necessary to analyze all of the tables. You had two
points you needed to know. Was it safe-- was it potent.
This you could decide without a detailed analysis of all
those tables. It war quite clear, and they could reach a
decision in a few ho rs, that the material was safe. There
was no production of paralytic polio by the vaccine in the
400,000 children, and it was obvious there was some measure
of protection afforded from comparing the placebos with the
vaccinated children. These were the two crucial points.
DR. SCHEELE: Members of our staff had participated
in the checking of the incidence of polio in those who got
vaccinated, If they had been aware of any serious problems,
I think they would have let us know.
QUESTION: It just seemed to me to be quite precipitous,
because it is a big report.
DR. SCHEELE: May I say one other thing. This is the
crux of a lot of things we do in medicine and science.
QUESTION: Two weeks --

DR. SEBRELL: Don't forget two weeks at that time would
have made a lot of difference in perhaps the protection

m.
im_
rm C
0
* CD
o.
S 0
CDg
0
--

K!